TY - JOUR
T1 - Antigen Capture and Immune Modulation by Bacterial Outer Membrane Vesicles as In Situ Vaccine for Cancer Immunotherapy Post-Photothermal Therapy
AU - Li, Yao
AU - Zhang, Kaiyue
AU - Wu, Yao
AU - Yue, Yale
AU - Cheng, Keman
AU - Feng, Qingqing
AU - Ma, Xiaotu
AU - Liang, Jie
AU - Ma, Nana
AU - Liu, Guangna
AU - Nie, Guangjun
AU - Ren, Lei
AU - Zhao, Xiao
N1 - Funding Information:
This work was supported by the grants from National Key R&D Program of China (2018YFE0205300), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB36000000), the CAS Project for Young Scientists in Basic Research (YSBR‐010), the Beijing Natural Science Foundation of China (Z200020), the Beijing Nova Program (Z201100006820031), the National Natural Science Foundation of China (32171384, 31800838, 31820103004, 31730032, 51861145302 U1904206, and 31870994), the Key Research Project of Frontier Science of the Chinese Academy of Sciences (QYZDJ‐SSW‐SLH022), the Beijing Natural Science Foundation (Z210017), the Innovation Research Group of National Natural Science Foundation (11621505), and the Hundred‐Talent Program of Chinese Academy of Sciences.
Publisher Copyright:
© 2022 Wiley-VCH GmbH.
PY - 2022/4/7
Y1 - 2022/4/7
N2 - Tumor antigens released from tumor cells after local photothermal therapy (PTT) can activate the tumor-specific immune responses, which are critical for eliminating the residual lesions and distant metastases. However, the limited recognition efficiency of released tumor antigens by the immune system and the immunosuppressive microenvironment lead to ineffective antitumor immunity. Here, an in situ multifunctional vaccine based on bacterial outer membrane vesicles (OMVs, 1-MT@OMV-Mal) is developed by surface conjunction of maleimide groups (Mal) and interior loading with inhibitor of indoleamine 2, 3-dioxygenase (IDO), 1-methyl-tryptophan (1-MT). 1-MT@OMV-Mal can bind to the released tumor antigens after PTT, and be efficiently recognized and taken up by dendritic cells. Furthermore, in situ injection of 1-MT@OMV-Mal simultaneously overcomes the immune inhibition of IDO on tumor-infiltrating effector T cells, leading to remarkable inhibition on both primary and distant tumors. Together, a promising in situ vaccine based on OMVs to facilitate immune-mediated tumor clearance after PTT through orchestrating antigen capture and immune modulation is presented.
AB - Tumor antigens released from tumor cells after local photothermal therapy (PTT) can activate the tumor-specific immune responses, which are critical for eliminating the residual lesions and distant metastases. However, the limited recognition efficiency of released tumor antigens by the immune system and the immunosuppressive microenvironment lead to ineffective antitumor immunity. Here, an in situ multifunctional vaccine based on bacterial outer membrane vesicles (OMVs, 1-MT@OMV-Mal) is developed by surface conjunction of maleimide groups (Mal) and interior loading with inhibitor of indoleamine 2, 3-dioxygenase (IDO), 1-methyl-tryptophan (1-MT). 1-MT@OMV-Mal can bind to the released tumor antigens after PTT, and be efficiently recognized and taken up by dendritic cells. Furthermore, in situ injection of 1-MT@OMV-Mal simultaneously overcomes the immune inhibition of IDO on tumor-infiltrating effector T cells, leading to remarkable inhibition on both primary and distant tumors. Together, a promising in situ vaccine based on OMVs to facilitate immune-mediated tumor clearance after PTT through orchestrating antigen capture and immune modulation is presented.
KW - antigen capture
KW - in situ vaccines
KW - indoleamine 2,3-dioxygenase
KW - photothermal therapies
UR - http://www.scopus.com/inward/record.url?scp=85124556107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124556107&partnerID=8YFLogxK
U2 - 10.1002/smll.202107461
DO - 10.1002/smll.202107461
M3 - Article
AN - SCOPUS:85124556107
SN - 1613-6810
VL - 18
JO - Small
JF - Small
IS - 14
M1 - 2107461
ER -